Professional Documents
Culture Documents
2016 E - Class Ypofysi 2 PDF-1
2016 E - Class Ypofysi 2 PDF-1
LHRH
ADH
FSH-LH
PRL
TSH
ACTH
OXYT
20
PRL
Stress
TRH,
CCK,
GABA,
DA
(-)
dopamine
prolactin
H Da PRL
PRL gene transcription, ,
Gudelsky GA. Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology
1997; 26: 41-54 1981; 6: 3-16
PRL Rec
DA
+
PRL
()
(DA )
&
LHRH
ADH
FSH-LH
GH
TSH
ACTH
PRL
OXYT
antipsychotic
efficacy
EPS
Parkinson
pituitary
lactotroph cells
D2 receptors
mesolimbic
mesocortical areas
HyperPRL
Bromocriptine BRC, D2 (1/2=2h)
Starting dose 1.25 mg (half a tablet) at bedtime for the 1st week, then up to 2.5 - 5 mg twice a day
Quinagolide D2 (1/2=17h)
second line treatment more potent then bromocriptine. Starting dose 25 g/day,
then up to 150-300 g/day
Cabergoline D2 (1/2=60h)
First line treatment, longer acting with fewer side effects 0.25-1.5 mg two times/week
DA
Dopamine
agonists
Bromocriptine
Ergot
(Parlodel)
2.5-10
mg/day
7.5 mg/
Lisuride
(Dopergine)
Ergot
0.1-0.2
mg/day
0.1 mg/
Quinagolide
(Norprolac)
Ergot
25-300
g/day
75 g/
Ergot
0.25-1
1 mg/
mg/TWW
Cabergoline
(Dostinex)
:
-
-,
Herring Bodies
Neurophysin-I
(oxytocin)
Neurophysin-ii
(ADH)
AVP
.
Osmolality
.. 2 V2 Rec
V1 Rec
High Osmolality
Osmoreceptors
Low Pressure
Receptors
ADH
Pain
Nausea
Vomiting
Surgical
Stress
Emotions
Standing
AITIA A.
( C, )
( , )
AVP
( )
..
( V2 )
: ( 8/Lysine ) IN
(DDAVP): ( Cys/1)
IV, SC IN ( 2 / .)
DDVAP T1/2 75m. ( AVP=10mn ) x 3000 . V2
AVP
(, /, ,
o , )
()
erlipressin ( V1 )
:
( U S A )
:
&
&
}
}
( + 2 =>
=> =
s
PRL initiate and maintain milk secretion by the mammary glands
Oxytocin, causes milk ejection
- ( v )
-
. :
( )